Advances and Prospects of 3-d Metal-Based Anticancer Drug Candidates

Farukh Arjmand, Huzaifa Yasir Khan, Sartaj Tabassum, et al.

PDF
ca. 213,99
Amazon iTunes Thalia.de Weltbild.de Hugendubel Bücher.de ebook.de kobo Osiander Google Books Barnes&Noble bol.com Legimi yourbook.shop Kulturkaufhaus ebooks-center.de
* Affiliate Links
Hint: Affiliate Links
Links on findyourbook.com are so-called affiliate links. If you click on such an affiliate link and buy via this link, findyourbook.com receives a commission from the respective online shop or provider. For you, the price doesn't change.

Springer Nature Singapore img Link Publisher

Naturwissenschaften, Medizin, Informatik, Technik / Nichtklinische Fächer

Description

This book reviews the potential of metallodrugs against different cancer. It summarizes the classification of metal-based anti-cancer drugs, their plausible biochemical and mechanistic pathways, combining drug strategies for hitting multiple therapeutic targets at the intracellular level, and advanced drug delivery strategies. The book covers the metallodrugs for the efficacious treatment of diverse cancerous strains and recent advances in drug delivery strategies that are used for developing these metal-based therapeutics as potent anticancer agents in vitro and in vivo. The book also covers different biophysical and analytical techniques for studying metal-ligand and metal-macromolecular interactions. The book further presents the recent examples of metallomics studies on the different types of cell death induced by metal-based anticancer drugs, especially on the three major forms of programmed cell death (PCD) in mammalian cells: apoptosis, autophagy, and regulated necrosis, alsocalled necroptosis. Lastly, the book explores the modulation of reactive oxygen species (ROS) by metallodrugs.


More E-books At The Same Price
Cover Habits
Youna Vandaele
Cover Primate Anatomy
Friderun Ankel-Simons
Cover Stroke Genetics
Pankaj Sharma

customer reviews

Keywords

Metallo-drugs, 3-D metals ions, Cytotoxicity activity, Anticancer chemotherapeutics, Molecular docking studies